ChromaCode

Executive Summary

ChromaCode is a US-based diagnostics company that has developed a novel High-Definition PCR (HDPCR) multiplexing platform, which enables highly multiplexed genomic testing from a single sample. The platform combines proprietary chemistry with cloud-based software analytics, offering a cost-effective and instrument-agnostic solution that delivers results comparable to next-generation sequencing (NGS) but with simpler workflows and faster turnaround times. The company initially focuses on oncology applications, where comprehensive genomic profiling is critical for personalized treatment decisions. By eliminating the need for expensive NGS equipment and complex bioinformatics, ChromaCode aims to democratize access to advanced genomic testing across a broader range of clinical settings. The HDPCR platform addresses significant unmet needs in the diagnostics market, particularly in oncology, where rapid and comprehensive testing can directly impact patient outcomes. ChromaCode's technology is designed to be compatible with existing PCR instruments, reducing barriers to adoption for laboratories. The company is well-positioned to capture market share in both clinical diagnostics and research applications. With a strong intellectual property portfolio and a focus on regulatory approvals, ChromaCode represents an attractive opportunity in the precision diagnostics space. The conviction score reflects the company's innovative technology, clear value proposition, and potential for near-term value creation.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance or CE marking for a new multiplex oncology panel70% success
• Q4 2026Strategic partnership with a major diagnostics company for distribution60% success
• Q1 2027Launch of a next-generation HDPCR platform or extension into new disease areas50% success